^
Association details:
| Biomarker: | Chr del(11q) |
|---|---|
| Cancer: | Small Lymphocytic Lymphoma |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FIXED-DURATION IBRUTINIB AND VENETOCLAX (I+V) VERSUS CHLORAMBUCIL PLUS OBINUTUZUMAB (CLB+O) FOR FIRST-LINE (CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRIMARY ANALYSIS OF THE PHASE 3 GLOW STUDY
Published date:
05/12/2021
Excerpt:
Pts were randomized 1:1, stratified by IGHV mutation and del(11q) status, to I+V (3 cycles ibrutinib 420 mg/d, followed by 12 cycles I+V with venetoclax...At 3 mo after end of treatment (EOT+3), rate of uMRD was significantly higher for I+V vs Clb+O in BM (51.9% vs 17.1%; p < 0.0001) and peripheral blood (PB; 54.7% vs 39.0%; p = 0.0259).
Secondary therapy:
venetoclax
Trial ID:
Source:
Title:
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Excerpt:
...- Del11q22.3 ataxia telangiectasia mutated (ATM) as detected by FISH...
Trial ID:
Source:
Title:
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
Excerpt:
The 5-year PFS rate was 92% in TN patients and 44% in R/R patients. Median PFS in R/R patients was 51 months; in those with del(11q), del(17p), and unmutated IGHV, it was 51, 26, and 43 months, respectively, demonstrating long-term efficacy of ibrutinib in some high-risk subgroups....efficacy and acceptable tolerability of ibrutinib over an extended time, providing the longest experience for Bruton tyrosine kinase inhibitor treatment in patients with CLL/SLL.
DOI:
10.1182/blood-2017-10-810044
Trial ID:
